{"schema_version":"secwatch.filing_event.v1","accession":"0001193805-23-000532","form_type":"8-K","ticker":"ARCT","cik":"0001768224","company_name":"Arcturus Therapeutics Holdings Inc.","filed_at":"2023-04-11T23:59:59+00:00","discovered_at":"2026-05-14T18:03:40.465368+00:00","generated_at":"2026-06-17T03:42:48.917147+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Meiji and CSL Seqirus to distribute Arcturus' COVID-19 vaccine ARCT-154 in Japan","bullets":["Meiji Seika Pharma entered a distribution agreement with CSL Seqirus for Arcturus' COVID-19 vaccine candidate ARCT-154 in Japan.","Phase III trial of ARCT-154 started Dec 12, 2022, targeting 780 participants; enrollment completed with 828 in Feb 2023.","Arcturus has a Collaboration and License Agreement with CSL Seqirus since Dec 8, 2022 for global rights to self-amplifying mRNA vaccines."],"urls":{"canonical":"https://secwatch.observer/filing/0001193805-23-000532","json":"https://secwatch.observer/filing/0001193805-23-000532.json","markdown":"https://secwatch.observer/filing/0001193805-23-000532.md","text":"https://secwatch.observer/filing/0001193805-23-000532.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1768224/000119380523000532/0001193805-23-000532-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1768224/000119380523000532/e618488_8k-arct.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-17T03:42:48.917147+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}